Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: Implications for paediatric treatment in the developing world

International Journal of STD and AIDS

Volumn 20, Issue 6, 2009, Pages 406-409

  Zhang, F ^a,b   Haberer, J ^a,c,d   Wei, H ^b   Wang, N ^a   Chu, A ^a   Zhao, Y ^a   Zhao, H ^b  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Harvard Initiative for Global Health   (United States)

Author keywords

Drug resistance; Highly active antiretroviral therapy; Paediatric

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG RESISTANCE; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHINA; COHORT STUDIES; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MALE; MUTATION; NATIONAL HEALTH PROGRAMS; PREVALENCE; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 67549094912     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2008.008357     Document Type: Article

References (16)

1. The Joint United Nations Programme on AIDS, World Health Organization. AIDS Epidemic Update: December 2006. Geneva: WHO; 2006. Available at: http://data.unaids.org/pub/EpiReport/2006/2006-EpiUpdate-en.pdf (accessed April 2008)
2. Bartlett J. 2006. Global HIV: Antiretroviral Therapy Scale Up and HIV/AIDS Care. Medscape Article. Available at: http://www.medscape.com/ viewarticle/544609 (accessed 15 April 2008)
3. Machado ES, Lambert JS, Afonso AO, et al. Overview of genotypic and clinical profiles of human immunodeficiency virus type 1-infected children in Rio De Janeiro, Brazil. An Acad Bras Cienc 2004;4:727-741 (Pubitemid 40019646)
4. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr 2007;46:187-193 (Pubitemid 47482614)
5. Zhang F, Haberer JE, Zhao Y, et al. Chinese pediatric HAART observational cohort: a one year analysis of clinical, immunologic, and virologic outcomes. J Acquir Immune Defic Syndr 2007;46:594-598 (Pubitemid 350191053)
6. Zhong P, Pan QC, Ning Z, et al. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai. AIDS Res Hum Retroviruses 2007;23:847-856 (Pubitemid 47267490)
7. Steele RG, Grauer D. Adherence to antiretroviral therapy for pediatric HIV infection: review of the literature and recommendations for research. Clin Child Fam Psychol Rev 2003;6:17-30 (Pubitemid 38979780)
8. Geretti AM. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors. AIDS Rev 2006;8:210-220 (Pubitemid 46138919)
9. Zhang M, Han XX, Cui WG, et al. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Jpn J Infect Dis 2008;61:361-365
10. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Recommendations for Public Health Approach. 2006. Geneva. Available at: http://www.who.int/hiv/pub/guidelines/art/en/ (accessed 15 April 2008)
11. Guidelines for the use of antiretroviral agents in pediatric HIV infection. 2006. United States Department of Health and Human Services. Available at: http:// aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?MenuItem= Guidelines& Search=Off&GuidelineID=8&ClassID=1 (accessed 15 April 2008)
12. Monitoring the Emergence of Antiretroviral Resistance: Report of a World Health Organization Consultation organized in collaboration with Istituto di Sanita and the International AIDS Society. 2001. World Health Organization: Rome, Italy. Available at: http://www.phppo.cdc.gov/dls/ila/cd/who-afro/ whocdscsrdrs200111web.pdf (accessed 15 April 2008)
13. Macassa E, Delaugerre C, Teglas JP, et al. Change to a once-daily combination including boosted atazanavir in HIV-1-infected children. Pediatr Infect Dis J 2006;25:809-814 (Pubitemid 44325783)
14. Ramos JT, De Jose MI, Duenas J, et al. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virsus-1-infected children experienced with three classes of antiretrovirals. Pediatr Infect Dis J 2005;24:867-873 (Pubitemid 41475920)
15. Martinez-Cajas JL, Wainberg MA. Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antivir Res 2007;76:203-221 (Pubitemid 47603256)
16. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20:139-149